VIP, or vasoactive intestinal peptide, is a short signal made by the body. It has been studied in people with lung conditions, with mixed results. It is coming soon to Promise.
Coming soon
You are on the list. We will email you when VIP (Vasoactive Intestinal Peptide) becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
VIP (Vasoactive Intestinal Peptide) is coming soon to Promise. Add your email and we'll let you know when visits open.
A licensed provider reviews every request; not everyone qualifies.
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A real person goes through your history and takes the time to get it right before anything is decided.
If a treatment isn't right for your history, you'll hear that plainly. That review is the whole point.
Made for your prescription by a licensed U.S. pharmacy and shipped in temperature-safe packaging.
Your care team checks in after it arrives. Adjust with your provider, or cancel at any time.
VIP (Vasoactive Intestinal Peptide) is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
VIP is studied for signaling through receptors, places on cells where messages attach, in blood vessels, lungs, the gut lining and immune cells.
Human studies have examined VIP in specific lung conditions. Small reports and larger trials ask different questions; none establishes a general immune benefit for everyone.
When visits open, a licensed provider will weigh your history, medicines and the evidence before deciding whether VIP is appropriate. They may request information or decline.
VIP is a signal the body already makes. Short for vasoactive intestinal peptide, it is studied for how blood vessels, lungs and immune cells respond. Human studies exist, but their findings are mixed. The larger COVID-19 trial did not meet its main goal, and lung research does not establish a general immune benefit.
VIP (Vasoactive Intestinal Peptide) is coming soon to Promise — add me to the list.
VIP is a neuropeptide: a short chain of amino acids, the building blocks of proteins, used in nerve signaling. It contains twenty-eight of those building blocks. Said and Mutt first isolated it from pig small intestine in 1970. The name records that discovery; its activity is not limited to the intestine.
“Vasoactive” means it affects blood vessels. VIP is a vasodilator, meaning it widens them and can lower blood pressure. That is part of its biology, not a reason to assume that extra VIP is safe because the body makes it.
VIP binds to receptors called VPAC1 and VPAC2. Receptors are places on cells where a signal can attach and pass a message inward. Researchers have examined this signaling in blood vessels, lungs, the gut lining and immune cells.
Work on lung immune cells has looked at inflammatory messages and cells that restrain immune responses. Mouse research has also examined communication between gut nerves and the gut lining. These studies ask how a system works. They do not establish that VIP prevents illness or that changing one signal helps everyone.
An early study published in 2003 examined inhaled VIP, breathed into the lungs, in eight people with pulmonary hypertension, meaning high blood pressure in the lung's blood vessels. Researchers reported changes in circulation measurements, but there was no placebo group receiving an inactive version for comparison.
A 2010 study examined inhaled VIP in twenty people with sarcoidosis, a condition involving clusters of inflammatory cells. It reported changes in immune cells and their signals. It was also uncontrolled: everyone received VIP, so changes could not be compared with a similar group receiving a placebo.
COVID-19 brought larger comparisons. A 2022 trial assigned 196 people with critical respiratory failure by chance to aviptadil or placebo. It missed its main goal of survival without respiratory failure. It reported a signal on a separate survival measure, which needs to be read alongside that missed main goal.
In the NIH-funded TESICO trial published in 2023, aviptadil given into a vein did not show a meaningful advantage over placebo on the main measure of recovery and survival. Researchers analyzed 461 adults who received a study infusion. Enrollment stopped because success on that measure was judged unlikely.
A smaller inhaled-aviptadil trial published in 2025 enrolled eighty hospitalized adults and reported a shorter hospital stay. It studied a different route and less critically ill patients than TESICO. Its authors noted limited numbers completing follow-up. That result needs confirmation; it does not cancel the larger trial's finding.
Reports about chronic inflammatory response syndrome, a label used for symptoms attributed to damp-building exposure, are a separate evidence line. A 2013 report followed twenty people without a randomized placebo comparison. Such reports cannot establish whether VIP itself caused the reported changes.
Aviptadil is synthetic VIP, made to copy the natural peptide. It is the name used in the COVID-19 trials. The molecule's identity does not make different preparations or study settings interchangeable.
A medicine combining aviptadil with phentolamine, another drug, has been authorized in parts of Europe for erectile dysfunction. Evidence about that combination does not establish an immune benefit from VIP alone.
Our immune support category also includes pages for Thymosin Alpha-1 and LL-37. Sharing a category does not mean that their findings apply to VIP. Each compound needs its own evidence and review.
VIP is not FDA-approved, and no FDA-approved U.S. product contains VIP or aviptadil. The FDA's May 14, 2026 nominations document places VIP in 503A Category 1, meaning under evaluation for compounding. It is not on the final 503A bulks list. A licensed provider may still prescribe — that decision is between you and your doctor.
In TESICO, low blood pressure, diarrhea, facial flushing and a fast heartbeat were more frequent during aviptadil infusions than placebo. Infusions were also stopped because of side effects more often with aviptadil than with placebo. Those findings belong in a safety discussion; a different setting cannot be assumed to carry the same risks or fewer risks.
When visits open, VIP will have its own intake questionnaire covering health history, medicines and the reason for the request. A licensed provider will review it and may request more information, prescribe or decline.
If prescribed, a licensed U.S. pharmacy will compound and dispense the medication. The formulation Promise will offer is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.
Your provider sets any protocol; Promise does not publish dosing. Follow-up check-ins from your care team will keep the plan under review. Joining the list today means receiving an email when visits open, not starting a visit now.
VIP is a short signaling peptide made by the body. Its full name is vasoactive intestinal peptide. It participates in nerve signaling and has been studied around blood vessels, lungs and immune cells. Human trials exist, but results differ by condition and study design. They do not establish a general immune benefit.
Yes. When visits open, VIP will be prescribed by a licensed provider after a review of your health history and compounded for you by a licensed U.S. pharmacy. It will not be a product labeled for laboratory use. A prescription will depend on the provider determining that VIP is appropriate for you.
A visit is a medical review, not a promise of a prescription. Once visits open, a licensed provider will consider your health history, medicines and reason for asking about VIP. They may request more information or decline. Joining the list now only means receiving an email when visits open.
No. VIP is not FDA-approved, and no FDA-approved U.S. product contains VIP or aviptadil. The formulation Promise will offer is a compounded medication, which is not reviewed by the FDA for safety, effectiveness, or quality. A licensed provider will decide whether it is appropriate after reviewing your history.
Not yet. VIP is coming soon to Promise — add me to the list on this page and we'll email you when visits open. This page explains the compound and the evidence before then. Joining the list does not start a visit or mean that a provider has decided to prescribe it.
Aviptadil is the synthetic form of VIP, made to copy the natural peptide. The name appears in human clinical trials, including studies in people hospitalized with COVID-19. A shared molecule does not make different preparations, routes or uses interchangeable. The name alone also does not establish safety or a benefit for a particular person.
The human evidence is mixed. Small uncontrolled lung studies reported changes in circulation or immune signals. The larger NIH-funded TESICO trial of aviptadil given into a vein did not meet its main goal, while a smaller inhaled trial reported a shorter hospital stay. These studies involved specific illnesses and cannot establish a broad immune benefit or a Promise protocol.
VIP sold online without a prescription may be labeled for laboratory use and come without a provider reviewing your history or a pharmacy dispensing a prescription for you. When visits open, Promise's process will involve a licensed provider's decision, a licensed U.S. pharmacy and follow-up check-ins from your care team.
Other Immune Support options a provider may consider.
Immune Support
A 28-amino-acid peptide derived from prothymosin alpha and produced by the thymus, studied for T-cell maturation and immune signaling.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Type a treatment, a goal, or a question.